
A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Brian Kennedy is a renowned biologist, leader in aging research, and director of the Center for Healthy Longevity at the National University of Singapore. In this episode, Brian shares insights from ongoing human aging studies, including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes. He presents two key models of aging—one as a linear accumulation of biological decline and the other as an exponential rise in mortality risk—and explains why traditional models of aging fall short. He also explains why most current aging biomarkers lack clinical utility and describes how his team is working to develop a more actionable biological clock. Additional topics include the potential of compounds like alpha-ketoglutarate, urolithin A, and NAD boosters, along with how lifestyle interventions—such as VO2 max training, strength building, and the use of GLP-1 and SGLT2 drugs—may contribute to longer, healthier lives.
Publisher
The Peter Attia Drive
Link
peterattiamd.com/briankennedy/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=250721-pod-briankennedy&utm_content=250721-pod-briankennedy-podfeed
Published
July 21, 2025
Duration
1h 57m
Format
Podcast
Category
Lifestyle · Health & Wellness
Source
RSS feed
The Peter Attia Drive
@peterattiadrive
#longevityscience #promisingcompounds #lifestyleinterventions
